Search

1. The effect of Medicare Part D on evergreening, generic entry, and drug prices

Author(s):

Sanzenbacher, Geoffrey T., author
Wettstein, Gal, author

Publication:

Chestnut Hill, MA : Center for Retirement Research at Boston College, May 2019

Subject(s):

Drug Costs
Drugs, Generic -- economics
Medicare Part D -- economics
Patents as Topic
United States
United States. Food and Drug Administration
Medical Expenditure Panel Survey (U.S.)

2. Trends in retail prices of generic prescription drugs widely used by older Americans: 2017 year-end update

Author(s):

Schondelmeyer, Stephen W., author
Purvis, Leigh, author

Publication:

Washington, DC : AARP Public Policy Institute, April 2019

Subject(s):

Drug Costs -- trends
Drugs, Generic -- economics
Prescription Drugs -- economics
United States

3. Price decreases for widely used generic drugs slow in 2017 after two years of substantial price drops

Author(s):

Schondelmeyer, Stephen W., author
Purvis, Leigh, author

Publication:

Washington, DC : AARP Public Policy Institute, April 2019

Subject(s):

Drug Costs -- trends
Drugs, Generic -- economics
Prescription Drugs -- economics
United States

4. Rx price watch report: price growth for brand name and specialty drugs more than offset price decrease for generic drugs

Author(s):

Schondelmeyer, Stephen W., author
Purvis, Leigh, author

Publication:

Washington, DC : AARP Public Policy Institute, September 2019

Subject(s):

Drug Costs -- trends
Drugs, Generic -- economics
Prescription Drugs -- economics
United States

5. Trends in retail prices of prescription drugs widely used by older Americans: 2017 year-end update

Author(s):

Schondelmeyer, Stephen W., author
Purvis, Leigh, author

Publication:

Washington, DC : AARP Public Policy Institute, September 2019

Subject(s):

Drug Costs -- trends
Drugs, Generic -- economics
Prescription Drugs -- economics
United States

6. Assessing user fees under the Generic Drug User Fee Amendments of 2017

Publication:

Silver Spring, MD : Center for Drug Evaluation and Research, May 2022

Subject(s):

Drug Industry -- legislation & jurisprudence
Drugs, Generic -- economics
United States
United States. Department of Health and Human Services
United States. Food and Drug Administration

7. Trends in manufacturer prices of generic prescription drugs used by older Americans-first quarter 2004 update

Author(s):

Gross, D. (David)

Publication:

Washington, D.C. : AARP Public Policy Institute, [2004]

Subject(s):

Drug Industry -- economics
Drug Industry -- trends
Drug Prescriptions -- economics
Drugs, Generic -- economics
United States

8. Rx watchdog report: trends in manufacturer prices of generic prescription drugs used by Medicare beneficiaries 2003 to 2007

Author(s):

Gross, David J.

Publication:

Washington, DC : AARP Public Policy Institute, c2008

Subject(s):

Drug Costs -- trends
Drugs, Generic -- economics
Medicare Part D -- economics
Forecasting
United States

9. Rx watchdog report: trends in manufacturer prices of prescription drugs used by Medicare beneficiaries, 2008 year-end update

Publication:

Washington, D.C. : AARP Public Policy Institute, c2009

Subject(s):

Drug Costs -- trends
Drugs, Generic -- economics
Medicare Part D -- economics
Prescription Drugs -- economics
United States

10. Biologics in perspective: the case for generic biologic drugs

Publication:

Washington, D.C. : AARP Public Policy Institute, c2009

Subject(s):

Biological Products -- economics
Drug Approval
Drugs, Generic -- economics
United States